Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TACROLIMUS Cause Therapy partial responder? 322 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 322 reports of Therapy partial responder have been filed in association with TACROLIMUS (Tacrolimus). This represents 0.4% of all adverse event reports for TACROLIMUS.

322
Reports of Therapy partial responder with TACROLIMUS
0.4%
of all TACROLIMUS reports
28
Deaths
49
Hospitalizations

How Dangerous Is Therapy partial responder From TACROLIMUS?

Of the 322 reports, 28 (8.7%) resulted in death, 49 (15.2%) required hospitalization, and 12 (3.7%) were considered life-threatening.

Is Therapy partial responder Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TACROLIMUS. However, 322 reports have been filed with the FAERS database.

What Other Side Effects Does TACROLIMUS Cause?

Off label use (8,718) Drug ineffective (6,214) Product use in unapproved indication (5,057) Acute kidney injury (4,005) Transplant rejection (3,526) Cytomegalovirus infection (3,320) Covid-19 (3,201) Drug interaction (2,896) Diarrhoea (2,854) Toxicity to various agents (2,845)

What Other Drugs Cause Therapy partial responder?

CYCLOPHOSPHAMIDE (1,397) RITUXIMAB (1,219) DEXAMETHASONE (1,199) PREDNISONE (1,176) PEMBROLIZUMAB (1,125) CARBOPLATIN (1,096) DOXORUBICIN (834) METHOTREXATE (775) VINCRISTINE (707) ETOPOSIDE (670)

Which TACROLIMUS Alternatives Have Lower Therapy partial responder Risk?

TACROLIMUS vs TACROLIMUS\TACROLIMUS ANHYDROUS TACROLIMUS vs TADALAFIL TACROLIMUS vs TAFAMIDIS TACROLIMUS vs TAFAMIDIS MEGLUMINE TACROLIMUS vs TAFASITAMAB

Related Pages

TACROLIMUS Full Profile All Therapy partial responder Reports All Drugs Causing Therapy partial responder TACROLIMUS Demographics